Autolus Therapeutics
AUTL
83 hedge funds and large institutions have $212M invested in Autolus Therapeutics in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 10 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 20
15% more capital invested
Capital invested by funds: $184M → $212M (+$27.6M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.84% less ownership
Funds ownership: 50.51% → 49.67% (-0.84%)
1% less funds holding
Funds holding: 84 → 83 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.6M |
| 2 |
Morgan Stanley
New York
|
+$500K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$371K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$362K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$331K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$2.6M |
| 2 |
AC
Armistice Capital
New York
|
-$1.26M |
| 3 |
MG
Marex Group
London,
|
-$824K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$558K |
| 5 |
Renaissance Technologies
New York
|
-$494K |
AUTL Hedge Fund Activity: Q2 2026 in Review
83 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2026, worth a combined $212M — up 15% from $184M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AUTL and 9 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 28 added.
The largest buyer was Millennium Management, adding an estimated $1.6M. The largest seller was Schroder Investment Management Group, cutting an estimated $2.6M.
- 83 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2026, down from 84 in Q1 2026.
- Funds reported $212M of Autolus Therapeutics stock for Q2 2026, up 15% quarter-over-quarter.
- 9 funds opened new Autolus Therapeutics positions in Q2 2026 and 10 closed out, a net change of -1 holder.
- The largest Autolus Therapeutics buyer in Q2 2026 was Millennium Management, an estimated $1.6M added.
- The largest Autolus Therapeutics seller in Q2 2026 was Schroder Investment Management Group, an estimated $2.6M sold.
Based on aggregated 13F filings for Q2 2026.